Additionally, less common mechanisms regulated by non-RTKs, such as loss of tumor suppressor genes, activation of inflammatory pathways, and alterations in downstream signaling pathways, need to be explored further to enhance our knowledge of therapy sensitivity in breast cancer, head and neck cancer and other cancers where EGFR plays a pivotal role in promoting tumorigenesis. This evidence concerns the gene EGFR and cancer.